Neurology
LatAm-FINGERS: Can lifestyle intervention help prevent dementia?
Dr Chinelo Ojukwu·4 days ago·5 min read
Medicine Central
Clinical education & evidence platform for UK primary care clinicians.
Clinical evidence moves faster than guidelines. Our medical team filters, curates, reports and educates on what has changed and how it impacts primary care practice. Providing you a trusted central reference point you can come back to, so you're always current.
Evidence-based content
NICE Guidelines aligned
Written for UK primary care
Editor's picks
Featured Articles
Obesity
Does chronic GLP-1 receptor agonist exposure remodel the pancreas? What the evidence actually shows
Preclinical studies show sustained molecular responses to GLP-1 receptor stimulation in pancreatic cell models. What does that mean for primary care, and what does it not show?
Medicine Central Editorial Team5 days ago · 7 min read
Cardiovascular Disease
Bariatric surgery versus GLP-1RAs: which delivers better CV outcomes in obesity?
11 days ago · 2 min read
Reference Points
Reference PointReference PointReference PointReference PointReference PointReference Point
Type 2 Diabetes
Diagnostic criteria, risk tools, annual care processes and referral pathways.
Chronic Kidney Disease
CKD staging, eGFR monitoring, renal protection and referral pathways.
Obesity
BMI classification, weight management tiers, risk stratification and referral pathways.
Cardiovascular Health
CVD risk assessment, hypertension management, lipid modification and referral pathways.
Asthma
Diagnostic criteria, risk stratification, annual review checklist and referral pathways per NG245.
COPD
Diagnosis, severity staging, smoking cessation, annual review and referral pathways per NG115.
Type 2 Diabetes
Type 2 Diabetes
BMI and type 2 diabetes: how much do ethnicity, age, and sex matter?
about 2 months ago · 5 min read
MASLD & Liver Disease
Making sense of abnormal liver blood tests: a MASLD heuristic for primary care
Around one in five adults have abnormal liver blood results. However, in the BALLETS primary care group, only 2.5% had a specific liver disease.
Dr Kevin Fernando3 months ago · 1 min read
Type 1 Diabetes
Cardiovascular Disease
Cardiovascular Disease
What your heart failure register is not telling you
Coding, registers and the four pillars in UK primary care
21 days ago · 5 min read
Cardiovascular Disease
Semaglutide for secondary cardiovascular prevention: An update that may have gone unnoticed – what NICE TA1152 means for primary care
NICE TA1152 establishes semaglutide 2.4 mg as a secondary cardiovascular-prevention treatment for adults with established cardiovascular disease and a BMI of at least 27 kg/m². Niraj Lakhani considers what this means for primary care.
Niraj Lakhani25 days ago · 8 min read
Chronic Kidney Disease
Chronic Kidney Disease
Chronic Kidney Disease in Primary Care: Small Changes That Make a Big Difference
CKD is common, but progression is not inevitable.
William Burlaceabout 2 months ago · 5 min read
Chronic Kidney Disease
Finerenone may slow kidney decline in glomerular disease
A prespecified exploratory analysis of the FIND-CKD trial reports slower eGFR decline with finerenone in chronic kidney disease due to glomerular diseases.
Medicine Central Editorial Teamabout 2 months ago · 5 min read
Women's Health
Women's Health
The Change We Forgot to Finish Talking About
This is a chance for women to get their mojo back.
Dr Shabana Hijazi11 days ago · 1 min read
Women's Health
MASLD is not just a man's disease
Most of us carry a mental model of fatty liver disease as something that turns up more often in men. A new narrative review in Diabetologia suggests it's time for an update.
2 months ago · 2 min read
AI & Digital Health
AI & Digital Health
FIVE questions to ask before you switch to ambient AI
Dr David Hindmarshabout 1 month ago · 2 min read
Elderly Care
AI in elderly care: two problems nobody is talking about together
AI is arriving in care homes — wearables, fall sensors, pain recognition apps. The potential is real. But two compounding problems are not getting enough attention: the data gap and the deployment gap.
Medicine Central Editorial Team4 months ago · 2 min read
Obesity
MASLD & Liver Disease
MASH: where the field is heading, and where primary care starts
New MASH licences clarify the fibrosis stages they cover, while the staging pathway remains the practical question for primary care.
Medicine Central Editorial Teamabout 1 month ago · 3 min read
Obesity
Biggest weight loss, biggest trade-off?
A BMJ network meta-analysis of 262 trials and 99,791 participants compares 19 obesity drugs. The ranking matters less than what sits behind each position.
Medicine Central Editorial Teamabout 2 months ago · 4 min read
In focus
GLP-1 & Obesity:
what every GP needs to know.
From semaglutide to tirzepatide: the evidence on weight management medications is moving fast. Our clinical team breaks down what the latest trials mean for prescribing in primary care.
Read the GLP-1 coveragePrescribing Safety
Prescribing Safety
One patient, three pains: a palliative care case study in opioid titration
This week, our expert insights will guide you through a case study from Jan Brassington’s webinar, ‘Managing Pain in Palliative Care.’ You can now watch it as an on-demand video on our CPD Webinars page!
Jan Brassington2 months ago · 3 min read
Prescribing Safety
MHRA tightens the warnings on 5-ARIs / DHT blockers
Medicine Central | Clinical Update. Safety warnings from MHRA on the use of 5-alpha reductase inhibitors, sometimes referred to as DHT blockers.
4 months ago · 2 min read
Mental Health
View all
Neurology
Neurology
Falling blood pressure and BMI in T2D may signal early dementia
25 days ago · 3 min read
Neurology
Fish oil and dementia prevention: what a new high-dose DHA trial found
A new randomised trial (PreventE4) confirmed that high-dose DHA supplementation reaches the brain — even in APOE ε4 carriers — but found no measurable benefit on hippocampal volume, cortical thickness, or cognitive scores over 24 months.
Medicine Central Editorial Team3 months ago · 4 min read
Psychiatric Health
Public Health
Elderly Care
Respiratory
Why Medicine Central
Built for the pace of modern primary care.
Primary care focus
Medicine Central is curated especially for UK primary care, with contributions from guest expert clinicians.
Evidence-based
Peer-reviewed sources only, with study design and limitations reported alongside the headline.
CPD-ready
CPD-eligible webinars let you log time against your appraisal portfolio.
Key publications in 50 words
MicroMedicine Central
Springer Nature· 9 September 2026
Tirzepatide and obstructive sleep apnoea: consistent signal across subgroups
Post hoc analyses of the two SURMOUNT-OSA phase 3 trials report that tirzepatide was associated with reductions in apnoea-hypopnoea index across every baseline subgroup examined, including age, sex, BMI, neck circumference and OSA severity. Improvement of at least one severity category occurred in 68% to 79% of tirzepatide-treated participants, against 30% to 36% on placebo. These analyses are descriptive and hypothesis-generating only.
The Lancet· 9 September 2026
RECOVER-VITAL: targeting viral persistence in post-COVID-19 condition (long COVID) using nirmatrelvir-ritonavir
Participants with long COVID were randomised to nirmatrelvir-ritonavir (15 or 25 days) or placebo across cognitive, autonomic, and exercise phenotypes. Neither regimen improved primary outcomes versus placebo, and secondary endpoints were also unchanged. No safety concerns emerged: no deaths occurred, and serious adverse events were similar, indicating no benefit in any subgroup.
Eur Heart J· 9 September 2026
VICTORION-Challenge: Inclisiran vs bempedoic acid for low-density lipoprotein cholesterol lowering in high-risk patients
402 patients with LDL-C ≥1.8 mmol/L were randomised to inclisiran or bempedoic acid. At day 150, the investigators reported greater absolute LDL-C reduction with inclisiran (-1.38 vs -0.45 mmol/L) and a comparable safety profile in high-risk patients not reaching guideline-recommended goals.
Palliat Care Soc Pract· 9 September 2026
Capacity and family decision-making, not the sedation itself, drove ethical difficulty at end of life
Moral case deliberation sessions with 231 clinicians in eight European countries found ethical difficulty in palliative sedation centred on autonomy: fluctuating capacity, patients deferring decisions to relatives, and families delaying agreement. Distress was lower where preferences were documented early and the rationale came from a team. The authors note community settings often lack both.
The Lancet· 9 September 2026
Rotavirus vaccine effectiveness against rotavirus and acute gastroenteritis mortality: an analysis of the MNSSTER-V dataset
MNSSTER-V pooled 27,252 under-5s (2007 to 2023) with acute gastroenteritis. In children >3 months who received routine vaccines, ≥1 rotavirus dose showed 75.8% adjusted effectiveness (95% CI 28.4–91.8; n=13,630) against rotavirus-positive gastroenteritis mortality, but 20.8% (–47.0–5.3; n=20,005) against all-cause gastroenteritis mortality.
This week's edition
This week's key publications, each summarised in 50 words by our clinical team.
Read MicroMedicine
Free professional account
Trusted by clinicians across the UK
- ✓Unlimited access to clinical evidence articles
- ✓Weekly newsletter curated for UK primary care
- ✓Free for registered UK healthcare professionals
GPsPharmacistsNursesDietitiansParamedicsPhysiotherapists
Join free We will never share your contact information.